October 19, 2022, delegates from Annexon and Ascent Development Services conducted a site visit and facility tour of Cotabato Regional and Medical Center. The team were composed by the Global Team Leader and Vice President for Global Clinical Operation of the Annexon Biosciences, Mr. Eric Humphriss, MBA, National Coordinating Principal Investigator, Dr. Jose Navarro, Medical Monitor, Dr. Robert Teoh and Project Manager Mr. Fengzhe Jin. This activity is to conduct site visit to the hospital for the protocol title: A Randomized, Double Blind, Placebo Controlled Phase 2/3 Study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ANX005 in cases with Guillain-Barre Syndrome. This study is headed by Dr. Fasl Goldanne B. Buenaflor as the Primary Investigator and is already approved by the PFDA and SJREB.
Guillain-Barre syndrome is a rare disorder in which your body's immune system attacks your nerves. Weakness and tingling in your hands and feet are usually the first symptoms. These sensations can quickly spread, eventually paralyzing your whole body. In its most severe form Guillain-Barre syndrome is a medical emergency. Most people with the condition must be hospitalized to receive treatment.
The primary goal of the study is to compare the efficacy of ANX005 versus placebo by measuring GBS disability Score (GBS-DS) over 26 weeks (6 months) in subjects recently diagnosed with GBS. CRMC as a tertiary apex and research hospital in both Region XII and BARMM will gain access to new research treatments before they are widely available. Cotabato Regional and Medical Center headed by our Medical Center Chief, Dr. Ishmael R. Dimaren, extends our gratitude to the visiting team for choosing the hospital to be included in such clinical trial.